Brentuximab Vedotin: all 145 studies that test it
Page 1 of 2. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.
- BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell LymphomasEnrolling by invitationNCT07258680Phase 3
- Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant MaintenanceNot yet recruitingNCT07178457Phase 3
- Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLRecruitingNCT07013565Phase 2
- BrECADD Therapy in Stage 2 B-IV Hodgkin LymphomaRecruitingNCT07002216Phase 2
- A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in IndiaRecruitingNCT06831370Phase 4
- A Study of BV-AVD in People With Bulky Hodgkin LymphomaRecruitingNCT06377566Phase 2
- BV-AVD-R Treatment Children Hodgkin's LymphomaEnrolling by invitationNCT06201507Phase 2
- CD30 Imaging in Diffuse Large B-cell LymphomaNot yet recruitingNCT06186986Phase 3
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingNCT05675410Phase 3
- Treatment Strategy for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT05595447Phase 2/3
- Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis FungoidesRecruitingNCT05357794Phase 2
- Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaRecruitingNCT05313243Phase 2
- Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's LymphomaRecruitingNCT05243693Phase 2
- Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT05180097Phase 2
- Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsRecruitingNCT05039073Phase 2
- PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyRecruitingNCT04745949Phase 2
- Brentuximab Vedotin in Early Stage Hodgkin LymphomaRecruitingNCT04685616Phase 3
- Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular LymphomaRecruitingNCT04587687Phase 2
- Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaRecruitingNCT04561206Phase 2
- BREntuximab Vedotin in SEcond LIne Therapy BEfore TransplantRecruitingNCT04378647Phase 2
- Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaRecruitingNCT03719105Early Phase 1
- Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome PatientsRecruitingNCT03587844Phase 2
- Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First RelapseRecruitingNCT03356054Phase 1/2
- A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)Active, not recruitingNCT05673785Phase 2Results posted
- A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell LymphomaCompletedNCT05442554Phase 4Results posted
- A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 ExpressionCompletedNCT04569032Phase 2Results posted
- Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLActive, not recruitingNCT04404283Phase 3Results posted
- A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell LymphomaTerminatedNCT03947255Phase 2Results posted
- Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaActive, not recruitingNCT03907488Phase 3Results posted
- Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II StudyActive, not recruitingNCT03517137Phase 2Results posted
- Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell LymphomaCompletedNCT03409432Phase 2Results posted
- BV-CHEP Chemotherapy for Adult T-cell Leukemia or LymphomaCompletedNCT03264131Phase 2Results posted
- Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin LymphomaActive, not recruitingNCT03233347Phase 2Results posted
- Brentuximab Vedotin for Systemic SclerosisCompletedNCT03222492Phase 1/2Results posted
- Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell LymphomaActive, not recruitingNCT03113500Phase 2Results posted
- Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin LymphomaActive, not recruitingNCT03057795Phase 2Results posted
- Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell TumorsTerminatedNCT02988843Phase 2Results posted
- A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin LymphomaActive, not recruitingNCT02979522Phase 1/2Results posted
- Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)CompletedNCT02939014Phase 2Results posted
- Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin LymphomaActive, not recruitingNCT02758717Phase 2Results posted
- Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02744612Phase 2Results posted
- Brentuximab Vedotin in Relapsed/Refractory Germ Cell TumorsTerminatedNCT02689219Phase 2Results posted
- Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell LymphomaTerminatedNCT02594163Phase 2Results posted
- A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)CompletedNCT02588651Phase 2Results posted
- An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin LymphomasCompletedNCT02581631Phase 1/2Results posted
- A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02572167Phase 1/2Results posted
- Dose Ranging Study of Brentuximab Vedotin in Adults With LupusTerminatedNCT02533570Phase 2Results posted
- Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin LymphomaCompletedNCT02505269Phase 2Results posted
- Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02429375Phase 1/2Results posted
- A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCLCompletedNCT02423291Phase 2Results posted
- Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive LymphomasCompletedNCT02388490Phase 2Results posted
- Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02227199Phase 1/2Results posted
- Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)TerminatedNCT02169505Phase 2Results posted
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin LymphomaActive, not recruitingNCT02166463Phase 3Results posted
- Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma PatientsCompletedNCT01994850Phase 1/2Results posted
- A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01990534Phase 4Results posted
- Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell LymphomaCompletedNCT01979536Phase 2Results posted
- A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell LymphomaCompletedNCT01950364Phase 1Results posted
- Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT01925612Phase 2Results posted
- Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin LymphomaActive, not recruitingNCT01920932Phase 2Results posted
- Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaCompletedNCT01909934Phase 4Results posted
- Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin LymphomaCompletedNCT01874054Phase 1/2Results posted
- Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30TerminatedNCT01841021Not applicableResults posted
- Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell LeukemiaCompletedNCT01807598Phase 2Results posted
- Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
- Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01780662Phase 1/2Results posted
- ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell LymphomasCompletedNCT01777152Phase 3Results posted
- Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin LymphomaCompletedNCT01771107Phase 1/2Results posted
- A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin LymphomaCompletedNCT01712490Phase 3Results posted
- Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)CompletedNCT01657331Phase 1/2Results posted
- Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin LymphomaCompletedNCT01578967Not applicableResults posted
- A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)CompletedNCT01578499Phase 3Results posted
- Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin LymphomaCompletedNCT01534078Phase 2Results posted
- Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01508312Phase 2Results posted
- Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin LymphomaCompletedNCT01492088Phase 1/2Results posted
- Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin LymphomaCompletedNCT01476410Phase 2Results posted
- Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous MalignanciesCompletedNCT01461538Phase 2Results posted
- Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression LevelCompletedNCT01396070Phase 2Results posted
- Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin LymphomaCompletedNCT01393717Phase 2Results posted
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)CompletedNCT01100502Phase 3Results posted
- A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin StudyCompletedNCT00947856Phase 2Results posted
- A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell LymphomaCompletedNCT00866047Phase 2Results posted
- A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin LymphomaCompletedNCT00848926Phase 2Results posted
- PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin LymphomaActive, not recruitingNCT05922904Phase 2
- Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis FungoidesSuspendedNCT05414500Phase 1
- A Safety Study of Brentuximab Vedotin in Participants With HIVWithdrawnNCT05244473Phase 1
- Open Label Extension Study of Brentuximab Vedotin in Early dcSScCompletedNCT05149768Phase 2
- Brentuximab Vedotin in Combination With CHEP in Patient With PTCLStatus unknownNCT05006664Phase 2
- Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaWithdrawnNCT04795869Phase 2
- Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsCompletedNCT04609566Phase 2
- Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell LymphomasWithdrawnNCT04334174Phase 2
- Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Active, not recruitingNCT03755804Phase 2
- Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin LymphomaActive, not recruitingNCT03712202Phase 2
- Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin LymphomaCompletedNCT03652441Phase 2
- BV After Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT03540849Phase 2
- OPTmizing Advanced Stage HodgkIn LymphoMa patIentS TherapyStatus unknownNCT03527628Phase 2
- Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With GemcitabineCompletedNCT03496779Phase 2
- Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)Status unknownNCT03474133Phase 2
- Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell LymphomasWithdrawnNCT03373305Phase 1
- Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin LymphomaCompletedNCT03302728Phase 1